The mechanisms of action are fundamentally different: GLP-1 agonists are synthetic or modified peptides designed to mimic incretin hormones and directly stimulate specific cellular receptors, while allulose is a simple sugar that undergoes passive absorption and excretion
Rare but serious risks include pancreatitis, gallbladder issues, and thyroid concerns
10.4062/biomolther.2017.178 25 CiomborK.WhisenantJ.AyersG.EngC.GoffL.CardinD.et al (2023)
Retatrutide is a Phase 3 investigational compound not yet approved by any regulatory agency as of June 2026
Kidney Int Suppl:S172S176 Gondouin B, Jourde-Chiche N, Sallee M, Dou L, Cerini C, Loundou A, Morange S, Berland Y, Burtey S, Brunet P, Guieu R, Dussol B (2015) Plasma xanthine oxidase activity is predictive of cardiovascular disease in patients with chronic kidney disease, independently of uric acid levels
Osteoarthritis FAQs What are the seven diagnostic criteria for RA